Nuvation Bio Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The interim financial statements are unaudited. Nuvation Bio is a clinical-stage oncology biopharmaceutical company with no approved products and no product or collaboration revenue reported.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $12.8 million | $18.8 million; down $5.9 million |
| General and administrative expense | $7.4 million | $7.7 million; down $0.4 million |
| Total operating expenses | $20.2 million | $26.5 million; down $6.3 million |
| Net loss | $14.8 million | $21.7 million; improved by $6.9 million |
| Net loss per share | $0.07 | $0.10 |
| Interest income | $7.1 million | $5.0 million |
| Cash used in operating activities | $15.7 million | $19.3 million |
Cash, cash equivalents and marketable securities totaled $597.0 million at March 31, 2024, compared with $611.2 million at December 31, 2023. Cash and cash equivalents alone were $34.5 million; marketable securities were $562.5 million. The company reported $608.1 million in current assets and $15.8 million in current liabilities, and no borrowings. Operating lease liabilities totaled $3.5 million. No operating margin is meaningful because the company reported no revenue.
Total assets were $613.1 million and stockholders’ equity was $594.0 million at quarter-end. The accumulated deficit on the balance sheet was $357.6 million. The company recorded a $1.5 million non-cash loss from the change in fair value of warrant liabilities and a $1.35 million unrealized loss on available-for-sale securities in other comprehensive loss.
Changes versus the prior period
- Operating expenses fell 23.8%, chiefly because third-party research and manufacturing costs declined after completion of the NUV-868 Phase 1 monotherapy study; R&D expense was down $5.9 million.
- Net loss improved 31.9%, while operating cash use declined by $3.6 million. These improvements do not reflect revenue growth; the company remains pre-commercial.
- Interest income increased $2.1 million, primarily due to higher Treasury yields. This was partly offset by a $1.6 million year-over-year increase in warrant fair-value expense.
- Investment purchases and maturities produced $7.5 million of investing cash flow, versus $52.0 million used in Q1 2023; this mainly reflects changes in the marketable-securities portfolio, not operating cash generation.
Outlook, developments and risks
- Management expects continued operating losses and negative operating cash flows. It stated that March 31 cash, cash equivalents and marketable securities should fund commitments for at least the next 12 months. The filing does not clearly quantify runway after the subsequent AnHeart acquisition.
- On April 9, 2024, after quarter-end, Nuvation completed its acquisition of AnHeart Therapeutics. The deal added taletrectinib, being studied in two pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer, and safusidenib, in a global Phase 2 study for IDH1-mutant glioma. Taletrectinib has FDA and China Breakthrough Therapy Designations; China’s NMPA accepted its applications for Priority Review. The transaction was expected to be accounted for as an asset acquisition.
- Consideration included approximately 27.6 million Class A shares, 851,202 Series A non-voting convertible preferred shares convertible into approximately 85.1 million Class A shares upon required stockholder approval, and warrants exercisable for approximately 2.9 million shares. The company also reserved approximately 15.9 million shares for assumed options and restricted stock units. These securities create material potential dilution.
- The existing pipeline also includes NUV-868, in a Phase 1b combination study, and NUV-1511, a Phase 1/2 drug-drug conjugate candidate. In January 2024, the FDA cleared an IND for NUV-1511.
- Key risks include clinical and regulatory failure or delay, reliance on third-party manufacturers and research organizations, the need for substantial future funding, AnHeart integration and operations in China, and uncertainty around intellectual property and commercialization. The company has no commercially approved products.
- The filing reports no pending significant legal proceedings expected by management to materially adversely affect financial position. It also states disclosure controls were effective; one sentence describing management’s evaluation refers to March 31, 2023, while the conclusion refers to March 31, 2024.
Important facts for investors to verify
- Confirm the post-acquisition cash position, integration costs and updated cash-runway estimate; the stated 12-month runway is based on March 31 resources and the filing does not clearly provide a revised post-deal estimate.
- Track AnHeart stockholder approval for conversion of preferred shares, resale and lock-up terms, and the resulting fully diluted share count.
- Verify timelines and outcomes for taletrectinib’s pivotal studies and regulatory reviews, and progress in the safusidenib, NUV-868 and NUV-1511 programs.
- Reconcile an apparent accumulated-deficit inconsistency: the balance sheet and liquidity note report approximately $357.6 million, while one MD&A passage states $361.2 million as of March 31, 2024.